Predictors of incident proteinuria among patients with SLE

Lupus Science and Medicine

Volumn 4, Issue 1, 2017, Pages

  Duarte García, Alí ^a   Barr, Erik ^b   Magder, Laurence S ^b   Petri, Michelle ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Lupus Nephritis; Systemic Lupus Erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NEPHRITIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 85047038286     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2016-000200     Document Type: Article

References (32)

1. Petri M, Perez-Gutthann S, Longenecker JC, et al. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
2. Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64.
3. Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
4. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002;112:726-9.
5. Freedman BI, Spray BJ, Heise ER, et al. A race-controlled human leukocyte antigen frequency analysis in lupus nephritis. The South-Eastern Organ Procurement Foundation. Am J Kidney Dis 1993;21:378-82.
6. Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161-72.
7. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
8. Costenbader KH, Desai A, Alarcón GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63:1681-8.
9. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000;160: 3136-40.
10. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009;36:63-7.
11. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329-33.
12. Esdaile JM, Abrahamowicz M, MacKenzie T, et al. The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994;37:359-68.
13. Goulet JR, MacKenzie T, Levinton C, et al. The long-term prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 1993;20:59-65.
14. Bastian HM, Alarcón GS, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 2007;46:683-9.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
18. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
19. Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013;65:753-63.
20. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
21. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634-43.
22. Ho A, Magder LS, Barr SG, et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
23. Orbai AM, Truedsson L, Sturfelt G, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 2015;24:42-9.
24. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
25. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15: 577-83.
26. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150-4.
27. Fessler BJ, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
28. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
29. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281-8.
30. Pons-Estel GJ, Alarcón GS, Hachuel L, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) 2012;51:1293-8.
31. Durán-Barragán S, McGwin G Jr, Vilá LM, et al. LUMINA (LIX): a multiethnic US cohort. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008;47:1093-6.
32. Leung YY, Szeto CC, Tam LS, et al. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology (Oxford) 2007;46:649-52.